title: Can spontaneous adverse event reporting systems really be used to compare rates of adverse events between drugs?
authors.forename: Paul M
authors.initials: PM
authors.lastname: Mertes
authors.forename: Anne B
authors.initials: AB
authors.lastname: Guttormsen
authors.forename: Torkel
authors.initials: T
authors.lastname: Harboe
authors.forename: S Gunnar O
authors.initials: SG
authors.lastname: Johansson
authors.forename: Erik
authors.initials: E
authors.lastname: Florvaag
authors.forename: Bent
authors.initials: B
authors.lastname: Husum
authors.forename: Lene H
authors.initials: LH
authors.lastname: Garvey
authors.forename: Morgens
authors.initials: M
authors.lastname: Kroigaard
authors.forename: Lars
authors.initials: L
authors.lastname: Gramstad
authors.forename: Kristin T
authors.initials: KT
authors.lastname: Kvande
authors.forename: Philippe
authors.initials: P
authors.lastname: Trechot
authors.forename: Jean M
authors.initials: JM
authors.lastname: Malinovsky
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D000707:Anaphylaxis / Q000139:chemically induced; D000732:Androstanols / Q000009:adverse effects; D000758:Anesthesia / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions; D006801:Humans; D000077123:Rocuronium; D014481:United States; D014673:Vecuronium Bromide / Q000009:adverse effects
chemical_list: D000732:Androstanols; D014673:Vecuronium Bromide; D000077123:Rocuronium